UniQure Investors Face April 13 Deadline to Lead Securities‑fraud Lawsuit
UniQure N.V. shareholders who purchased ordinary shares between September 24 and October 31, 2025, have until April 13, 2026 to file a motion to serve as lead plaintiff in a securities‑fraud class action. The lawsuit, filed by Rosen Law Firm, alleges the biotech misled investors about FDA approval of its Huntington’s disease pivotal study and the timing of its Biologics License Application.
Sibel Health Wins FDA Clearance for Maternal-Fetal Monitoring Platform
Sibel Health announced FDA 510(k) clearance for ANNE Maternal, a wireless wearable that continuously monitors a pregnant woman's vital signs, fetal heart rate, and uterine activity. The platform adds visual and audio alarms plus an automated Modified Early Obstetric Warning...
Sarcopenia -- New Clues
Recent preclinical and clinical work links low‑grade inflammation to age‑related muscle loss, or sarcopenia, and shows that ibuprofen can blunt this process. In 20‑month‑old rats, a five‑month ibuprofen regimen cut inflammatory markers by up to 60% and boosted post‑prandial muscle...
Fragments vs the E3 Ligase KLHL12
Researchers at Vanderbilt screened 13,824 fragments against the E3 ligase KLHL12, a protein overexpressed in many cancers but absent from heart tissue. The campaign yielded 35 initial hits, with compound 7k emerging as the most potent, displaying sub‑micromolar affinity in...
Person Functionally Cured of HIV After Bone Marrow Transplant From Sibling
A 63‑year‑old man achieved functional cure of HIV after receiving a bone‑marrow transplant from his brother, who carries two copies of the CCR5 Δ32 mutation that blocks the virus’s primary entry point. The donor cells fully engrafted in the recipient’s blood,...
COSMOS Pharmaceutical Posts Nine‑month Profit Rise to ¥22.7 Bn, Revenue up 7.7%
COSMOS Pharmaceutical Corp (3349.T) posted a nine‑month net profit of ¥22.748 bn, up from ¥22.343 bn a year earlier, while revenue rose 7.7% to ¥810.380 bn. The results highlight continued top‑line momentum for the Tokyo‑listed biotech firm.
Appointments and Advancements for April 13, 2026
On April 13, 2026 three biotech firms filed patents on novel drug candidates. Accure Therapeutics disclosed oligopeptide derivatives that inhibit matrix metalloproteinases MMP‑2 and MMP‑9, enzymes linked to cancer invasion and fibrosis. Merck Sharp & Dohme (MSD) introduced indazole‑based blockers of HCN1/2...
Allogene’s First Cut of Data on ‘Off-the-Shelf’ CAR-T Shows Promise
Allogene Therapeutics reported that its off‑the‑shelf CAR‑T candidate cleared all detectable lymphoma cells in just over half of trial participants. The interim analysis stems from the pivotal ALLO‑501/ALLO‑501A study in relapsed or refractory B‑cell lymphoma. Researchers highlighted a complete molecular...
GSK Reports Strong Results for B7-H4 ADC in Gynecological Cancers
GSK’s investigational antibody‑drug conjugate mocertatug rezetecan (Mo‑Rez) demonstrated robust activity in its Phase 1 BEHOLD‑1 trial, achieving a 62% objective response rate in platinum‑resistant ovarian cancer and 67% in recurrent or advanced endometrial cancer. The drug targets the B7‑H4 immune checkpoint,...
Orforglipron
Orforglitron, an oral non‑peptide GLP‑1 receptor partial agonist developed by Eli Lilly and Chugai, received FDA approval for chronic weight management. The drug distinguishes itself from oral semaglutide by requiring no fasting or special dosing constraints, enabling once‑daily administration. Clinical trials...
Researchers Use Nanomaterials and Ultrasound to Create Light Inside the Body
Stanford researchers have created a noninvasive method that uses focused ultrasound to activate biocompatible ceramic nanoparticles, generating light at any point inside the body. The proof‑of‑concept, demonstrated in mice, produced blue 490 nm light that could stimulate neurons and mimic photodynamic...
USP Adds Tamiflu, Trulicity to Vulnerable List as Upstream Analysis Reshapes Supply Concerns
The United States Pharmacopeia (USP) has refreshed its vulnerable medicines list, adding Tamiflu (oseltamivir) and Trulicity (dulaglutide) after expanding its risk assessment to include key starting materials (KSMs). The new analysis shows 48 of the 100 flagged drugs depend on...
Allogene Stock Sails After CAR T Clears Residual Lymphoma in Early Data Cut
Allogene Therapeutics reported interim results from its Phase 2 ALPHA3 trial showing its off‑the‑shelf CAR‑T product cema‑cel cleared measurable residual disease in 58.3% of patients versus 16.7% in the observation arm. The therapy also achieved a 97.7% drop in circulating tumor...
How This Biotech Stock Skirted Today's Selloff
Revolution Medicines (RVMD) surged 35.5% to $131.35, briefly touching a record $135.81 after reporting that its pancreatic‑cancer pill daraxonrasib cut death risk by 60% in a Phase 3 trial. Leerink and Guggenheim raised price targets to $147 and $174, respectively. The...
Hidden Antivirals Discovered in a Plant-Derived Supplement
Researchers identified a new family of trace molecules, dubbed dicitriosides, hidden in a 90 %‑purity isoquercitrin supplement. These triterpenoid‑cinnamate compounds exhibit nanomolar potency against Ebola, Zika and SARS‑CoV‑2, outperforming the original mixture by roughly 25‑fold. The antiviral activity was isolated to...
BioNTech's HER2 ADC Succeeds in Phase 2 Study, FDA Filing Planned
BioNTech announced that its HER2‑targeted antibody‑drug conjugate, trastuzumab pamirtecan (formerly BNT323), achieved robust efficacy in a Phase 2 trial of HER2‑positive metastatic breast cancer. The study reported a 45% overall response rate and a median progression‑free survival of 8.2 months, with...
Revolution Rises 40% as Pancreatic Cancer Drug Doubles Survival
Revolution Medicines announced that its oral RAS inhibitor daraxonrasib doubled overall survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma, achieving 13.2 months versus 6.7 months on chemotherapy. The Phase 3 RASolute 302 interim analysis was declared final, prompting the company...
Rigorous Trials, Not Hype, Prove Cancer Drug Value
Today's $RVMD study outcome in pancreatic cancer is a good lesson for all the $IBRX @DrPatrick fans. Stop with all the hand-waving "cancer cure" podcasting social media nonsense. Shut up and run well-designed clinical trials with definitive endpoints. If you have...
Nanodiscs Reveal Antibody Interactions for HIV, Ebola Vaccines
Nanodisc technology enables viral surface proteins from HIV and Ebola to be studied within lifelike membrane environments, offering new insights into antibody interactions and accelerating the development of next-generation vaccines. vaccinedesign
The IPO Buzz: Obesity-Focused Kailera Therapeutics Sets $500 Million IPO
Kailera Therapeutics, an obesity‑focused biotech developing a weekly GLP‑1 injection and a daily oral pill, filed an S‑1/A to raise $500 million. The company will offer 33.33 million shares at $14‑$16 each, which would place its market value near $1.8 billion if priced...
Leukogene Therapeutics Announces Two Presentations at the AACR Annual Meeting 2026 Highlighting MHC Class II-Engager Immunotherapies
Leukogene Therapeutics announced two poster presentations at the 2026 AACR Annual Meeting in San Diego, showcasing its MHC class II‑engager immunotherapy candidates for acute myeloid leukemia and pancreatic cancer. The posters will be displayed during the Immunology session on bi- and...
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Who...
Daiichi Sankyo and Merck have received FDA acceptance and Priority Review for the Biologics License Application of ifinatamab deruxtecan, a first‑in‑class B7‑H3‑directed antibody‑drug conjugate, targeting adult patients with extensive‑stage small cell lung cancer (ES‑SCLC) who progressed after platinum chemotherapy. The...
Genetically Engineered Pets Are Coming
Genetic engineering, especially CRISPR, is moving beyond medicine and food into the pet market. U.S. regulators classify gene edits for pets as animal drugs, so companies must demonstrate safety for the animal and environment. Start‑up projects such as the Los...
The AI Value Gap and Why Validation Is a Practical First Win for Life Sciences
AI adoption in life‑sciences is hampered by a wide value gap, with only about 40% of firms seeing EBIT impact and most gains under 5%. A practical entry point is FDA‑oriented computer system validation (CSV) and computer software assurance, where...
IDEAYA/Servier PKC Drug Aces Uveal Melanoma Trial
IDEAYA’s PKC inhibitor darovasertib, combined with Pfizer’s crizotinib, achieved a statistically significant improvement in progression‑free survival in the phase 2/3 OptimUM‑02 trial for HLA‑A*02:01‑negative metastatic uveal melanoma. Median PFS extended to 6.9 months versus 3.1 months for investigator‑chosen immunotherapy, and the...
Swiss Study Finds 37‑Protein Signature That Sets Centenarians Apart
Researchers at the University of Geneva and the University of Lausanne discovered 37 blood proteins that keep centenarians biologically youthful. The finding pinpoints a clear molecular factor behind extreme longevity, sparking excitement in the biohacking community.
China-Indonesia Partnership Aims to Produce Millions of HPV Vaccine Doses Locally
Indonesia's drug regulator, BPOM, announced a deepened partnership with Chinese biotech firms to fast‑track domestic production of the nine‑valent HPV vaccine. The collaboration seeks to generate millions of affordable doses annually, easing access for women across the archipelago.
Telix, Regeneron Ink $40M 50/50 Deal to Co‑Develop Next‑Gen Radiopharmaceuticals
Telix Pharmaceuticals and Regeneron Pharmaceuticals have struck a 50/50 partnership, with Regeneron paying $40 million upfront for access to Telix’s radiopharmaceutical platform on four initial cancer programs. The deal includes options for four more programs, milestone payments up to $535 million per...
STAT+: Pharmalittle: We’re Reading About a Pancreatic Cancer Pill, FDA Rejecting a Replimune Drug Again, and More
Revolution Medicines reported that its KRAS‑targeting oral pill daraxonrasib more than doubled median overall survival for metastatic pancreatic cancer patients, achieving 13.2 months versus 6.7 months on standard chemotherapy. The company will leverage a FDA priority‑review voucher to seek accelerated...
Hisamitsu Pharmaceutical Posts 12% Profit Drop Despite 4.5% Revenue Rise
Hisamitsu Pharmaceutical Co. announced full‑year earnings of ¥19.16 bn, a 12% fall from the prior year, even as revenue rose 4.5% to ¥163.0 bn. The mixed results underscore challenges in its biotech‑focused product lines amid a tightening Japanese market.
AbbVie Enters World of Pain in up to $715M Deal with China’s Haisco
AbbVie has signed an exclusive licensing agreement with China’s Haisco Pharmaceutical Group that could be worth up to $715 million. The deal grants AbbVie rights to a portfolio of pain‑related compounds ranging from preclinical to Phase 1 stages in China. This marks...
Amgen Pipeline’s Next Growth Cycle: Replacing Its Old Blockbusters
Amgen posted $36.8 billion in 2025 revenue, a 10% year‑on‑year rise, but its legacy blockbusters such as Enbrel, Xgeva and Otezla are under pressure from biosimilars and U.S. pricing reforms. Growth is now being driven by cardiovascular drugs, rare‑disease assets acquired...
Module 3 Quiz
Drug Hunter’s online learning platform has released a Module 3 quiz covering the Hit Discovery section of its pharmaceutical curriculum. The quiz is part of a broader, subscription‑based course that guides users through early‑stage drug‑target identification. Learners must sign in or...
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
Personalis will showcase its ultrasensitive NeXT Personal ctDNA assay at the AAC 2026 meeting, including an oral presentation on neoadjuvant pembrolizumab in high‑risk colorectal cancer. The company will also debut Real‑Time Variant Tracker, a new MRD test option that longitudinally monitors therapy‑resistance...
Pharma Firms Accelerate Regional Capacity Building to Secure GLP-1 Supply and Mitigate Geopolitical Risks
Pharma companies are reshaping supply chains by regionalizing GLP‑1 manufacturing to mitigate geopolitical risks and meet soaring demand for metabolic therapies. Eli Lilly announced a $3 billion investment in China and a ¥20 billion ($126 million) upgrade of its Kobe plant in Japan, targeting...
Regeneron Enters Radiopharma Ring with up to $4.3B Telix Alliance
Regeneron Pharmaceuticals has struck a partnership with Australian biotech Telix, committing $40 million to launch four initial radiopharmaceutical programs and securing an option for four more. The deal splits development and commercialization costs and profits equally, while Telix stands to earn...
One Gene Therapy Platform Could Cure Obesity and More
Eric Kelsic makes the compelling case on using gene therapy technology to eventually treat common diseases, like obesity: “Fundamentally, we all share the same genetics." Because our bodies run on the same genetic blueprint, a disease - whether common or rare -...
Pancreatic Cancer Drug Nearly Doubles Survival in Trial
Revolution pancreatic cancer drug nearly doubles survival in key trial https://t.co/SvJicU0LIz @ByJonGardner $RVMD + 38%
Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs Viral Infection Results in Approximately 20 Minutes
Beckman Coulter Diagnostics, a Danaher company, received CE Mark approval for the Access MeMed BV assay, a high‑throughput host‑response test that distinguishes bacterial from viral infections in about 20 minutes. The assay runs on existing DxI 9000 and Access 2...
Revolution Medicines' Pancreatic Cancer Drug Shows Late‑Stage Success
This is big. All cancers suck. Pancreatic somehow manages to suck even more. Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial https://t.co/rFVsvi0mQD
Comprehensive Genomic Landscape of Small Bowel Adenocarcinoma Revealed
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases [May 14, 2024] Aparicio et al. @BrJCancer https://t.co/xfznlhD4fh #sbcsm #cagenome HT @OncoThor
The Era of Big Pharma’s One-Size-Fits-All Pipeline Is Fading
Big Pharma’s pipeline volume remained steady in early 2026, but its composition is fragmenting. While the ten largest developers still dominate, the number of boutique firms with one or two candidates surged past 4,000, reflecting investor appetite for niche innovation....
Multiplexed In‑Vivo Screening Drives Next‑Gen Drug Development
Multiplexed in vivo screening is the future of drug development. @ManifoldBio is multiplexing protein therapies in vivo. @GordianBio is multiplexing gene therapies in vivo. @waypointbio is multiplexing cell therapies in vivo. GT Bio is multiplexing LNPs in vivo. 50Y portcos all https://t.co/DT2AwXbKtB
ALLO May
Has $ALLO found a niche for allo Car-T at last? It's early days, so the answer is maybe. Via @APEXONCO -> https://t.co/bO3A1hpAY8
Peptides Are Potent Therapeutics, yet only a Few Qualify.
“The big picture is that peptides are a legitimate, powerful class of therapeutics, but the legitimacy is confined to a relatively narrow subset of them.” —Peter Attia 👨🏻⚕️
Integrate scRNA‑seq PBMCs only After Evaluating Batch Effects
🧵 Should you integrate single-cell RNA-seq datasets or not? You've got PBMCs from multiple donors. Merge them—or keep them separate? Let's break it down.
Pancreatic Cancer Trials Yield Only 1‑2 Month Gains
I remember years ago in pancreatic cancer trials you were realistically looking for 1 to 2 months improvement in survival (at best) in pancreatic cancer trials. Bravo $RVMD.👏
Second‑line RVMD Improves Pancreatic Cancer Survival over First
As noted by others, the $RVMD dara mOS in 2nd line PDAC is better than mOS for current first-line regimens.
Low‑Cost Vaccine Creator Outshines Rogan’s Diet Critique
I make low cost vaccines for global health, including a Covid vaccine technology for $2-3 per dose reached 100 million people, bypassed big pharma, didn’t make money, and all these Rogan types can talk about is a joke I made...
Daraxonrasib Halves Pancreatic Cancer Mortality, Doubles Survival
Finally, best news of the morning (and something you didn't expect so soon)... Revolution Medicines $RVMD daraxonrasib Ph3 results in second-line pancreatic cancer. Median overall survival in ITT patients (KRAS mutants + wild type combined) Dara 13.2 months vs chemo 6.7...